Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial
Official title:
Acupressure for the Prevention of Chemotherapy-Associated Nausea and Vomiting in Children
RATIONALE: Using acupressure wrist bands to press and stimulate nerves at an acupressure
point on the inside of the wrist may help control nausea and vomiting caused by chemotherapy.
PURPOSE: This randomized clinical trial is studying how well acupressure works in preventing
nausea and vomiting in young cancer patients receiving chemotherapy.
OBJECTIVES:
- Determine the feasibility of implementing an acupressure therapy for the prevention of
chemotherapy-associated nausea in children with cancer.
- Test the hypothesis that acupressure bands will prevent chemotherapy-associated nausea
and vomiting in children, when compared to placebo acupressure (wrist bands without
acupressure).
- Develop a competitive grant application for a large, multi-institutional randomized
controlled trial of the efficacy of acupressure in preventing chemotherapy-associated
nausea in children.
OUTLINE: This is a prospective, randomized, placebo-controlled, crossover, pilot study.
Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients wear Sea-Band elastic acupressure wristbands on each wrist beginning
approximately 1 hour before beginning their first inpatient chemotherapy session and
continuing for at least 24 hours after completing chemotherapy. Patients do not wear
wristbands for their second chemotherapy session. Patients wear placebo wristbands on
each wrist beginning approximately 1 hour before their third chemotherapy session and
continuing for at least 24 hours after completing chemotherapy.
- Arm II: Patients wear placebo wristbands on each wrist beginning approximately 1 hour
before their first chemotherapy session and continuing for at least 24 hours after
completing chemotherapy. Patients do not wear wristbands for their second chemotherapy
session. Patients wear Sea-Band acupressure wristbands on each wrist beginning
approximately 1 hour before their third chemotherapy session and continuing for at least
24 hours after completing chemotherapy.
All patients also receive standard antiemetic therapy.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Completed |
NCT00985868 -
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT00949117 -
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
|
Phase 2 | |
Completed |
NCT00253474 -
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
|
Phase 1 | |
Completed |
NCT00281944 -
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00003070 -
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
|
Phase 3 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003754 -
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
|
Phase 2 | |
Completed |
NCT00016861 -
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
|
Phase 1 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00898794 -
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
|
N/A | |
Terminated |
NCT00429702 -
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
|
Phase 2 | |
Completed |
NCT00459238 -
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
|
N/A | |
Completed |
NCT00387920 -
Sunitinib in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00138216 -
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00070473 -
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
|
Phase 1 |